Reducing Stigma in People Who Inject Drugs (PWID) With HIV Using a Rapid Start Antiretroviral Therapy Intervention (ART)
Launched by YALE UNIVERSITY · Aug 2, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the experience of people who inject drugs and are living with HIV by exploring a quicker way to start treatment with antiretroviral therapy (ART). The goal is to find out how soon healthcare providers can begin this treatment after a person is diagnosed with HIV, which may help reduce stigma and improve health outcomes. To do this, researchers will talk to both experts and individuals who inject drugs to understand their experiences and gather insights.
Participants in this study will include adults who inject drugs and are seeking ART, either in the general population or in a prison setting. To be eligible, participants need to be willing to receive treatment and provide informed consent. Healthcare providers who prescribe ART will also be involved, as they will need to agree to use the new approach being tested. The trial will be conducted in selected HIV clinics and prisons, and while participants will receive the necessary medications, the focus is on how quickly they can start treatment after diagnosis. This study is not yet recruiting participants, but it aims to make a positive impact on the lives of those affected by both HIV and drug use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- PWID in general population:
- • Be a PWID from the general population enrolling into ART services at one of the study's HIV clinics. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD).
- • Provide informed consent.
- • HIV clinicians prescribing ART
- • 1. Be the HIV clinician who prescribes ART for a PWID in one of the selected clinics.
- • 2. Be willing to use the RS-ART protocol.
- • 3. Be at least 18 years old. No minors below age 18 will be enrolled in the study.
- • 4. Provide informed consent.
- PWID in prison population:
- • Be a PWID enrolling into ART services at Kajang prison. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD).
- • Provide informed consent.
- Exclusion Criteria:
- • -
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kajang, , Malaysia
Kuala Lumpur, , Malaysia
Kuala Lumpur, , Malaysia
Kuala Lumpur, , Malaysia
Patients applied
Trial Officials
Frederick L Altice, MD
Principal Investigator
Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported